We have produced a large library of nucleoside and nucleotide analogs prodrugs that specifically target viral RNA polymerases. Based on extensive knowledge and years of experience discovering and developing antivirals, our team of scientists has designed product candidates that include specific chemical modifications intended to enhance antiviral activity and maximize selectivity.
Unique prodrugs of nucleotide analogs are intrinsic to Atea’s innovative platform for developing orally administered, direct-acting antiviral therapies.
Atea is advancing oral product candidates that are designed to be potent and selective, including nucleos(t)ide analogs being developed as either monotherapy or in combination with other antiviral agents. Each of the nucleos(t)ide analogs Atea is currently advancing in clinical development, specifically bemnifosbuvir (AT-527) and AT-752, have been derived from Atea’s proprietary nucleotide platform. These product candidates are designed to inhibit the enzymes central to viral replication while avoiding toxicity to host cells.